Analyst Comment

New AI model boosts early osteoporosis diagnosis for ageing populations

More than two-thirds of vertebral fractures occur without pain, complicating early detection.

Credit: Bert van Dijk/Getty images.

Powered by

Osteoporosis is the most common metabolic bone disorder worldwide and is the leading cause of fragility fractures.

It is a systemic skeletal condition marked by decreased bone mass and the deterioration of bone structure, which increases the risk of fractures, especially in the spine, hip, distal forearm, and proximal humerus.

These fractures greatly contribute to morbidity, often necessitating long recovery periods and full-time care for many patients.

Despite its significant impact, osteoporosis often goes unnoticed until a fracture occurs, earning it the label of a ‘silent disease’.

A June 2024 study conducted by Qiu and colleagues and published in Frontiers in Artificial Intelligence has shown the development of a novel deep neural network (DNN) model with an effective algorithm for early diagnosis and intervention of osteoporosis.

Osteoporosis typically develops over several years before resulting in a fracture that brings it to medical attention.

More than two-thirds of vertebral fractures occur without pain, complicating early detection.

Common symptoms include back pain from fractured vertebrae, which can lead to visible deformity or reduced mobility.

The condition can also cause a stooped posture, known as kyphosis, as vertebral fractures cause the spine to collapse and bend forward, further affecting the individual’s physical functionality and quality of life.

The recent study introduces a novel model aimed at improving the diagnosis and treatment of osteoporosis, particularly in the ageing population.

Existing AI models for diagnosing osteoporosis such as logistic regression and support vector machines, often fall short due to their simplistic data analysis and limited accuracy.

These models can struggle with complex medical data and predicting osteoporosis risk accurately.

The new DNN model overcomes these issues by using advanced techniques to analyse large and diverse data sets.

This results in higher accuracy and better identification of at-risk patients, making it a more reliable tool for early diagnosis and treatment, ultimately improving patient care.

The researchers utilised a comprehensive dataset to develop their DNN model, incorporating diverse patient demographics and clinical variables.

By training the model on this extensive dataset, they aimed to create an algorithm capable of accurately predicting osteoporosis risk and identifying patients who would benefit from early intervention.

The methodology emphasised the importance of using a large, varied data set to ensure the model’s robustness across different populations.

This approach underscores the potential of AI in handling complex medical data and providing actionable insights.

In the course of their study, the researchers employed various machine learning techniques to refine the DNN model.

They compared its performance against logistic regression and support vector machines.

In this study, the DNN model outperformed these conventional methods in accuracy, sensitivity, and specificity.

This suggests that the AI-driven model can more reliably identify patients at risk of osteoporosis, potentially leading to earlier diagnosis and better-targeted treatments.

The study’s findings highlight the significant advantages of incorporating AI into osteoporosis care.

The DNN model demonstrated a high level of accuracy in predicting fracture risk and identifying patients who could benefit from preventive measures.

This capability is crucial, as early diagnosis and treatment can significantly reduce the incidence of fractures and improve quality of life for patients.

Moreover, the model’s ability to process and analyse large volumes of data quickly and accurately makes it a valuable tool for healthcare providers.

Together, the development of this DNN model represents a major advancement in the field of osteoporosis diagnosis and treatment.

For pharmaceutical companies, this innovation offers new opportunities for developing targeted therapies and preventive measures.

By leveraging AI technology, the healthcare industry can improve patient outcomes and reduce the burden of osteoporosis.

As this model is further validated and integrated into clinical practice, it has the potential to transform osteoporosis care and enhance the well-being of ageing populations globally.

Go to article: Home | Cell and gene therapy approvals drive paradigm change in manufacturingGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: Syngene Company InsightGo to article: SyngeneGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: PCI Pharma ServicesGo to article: AlfatestLAB - CPHIGo to article: RHEACELL Company InsightGo to article: In DepthGo to article: Cell and gene therapy approvals drive paradigm change in manufacturingGo to article: After the Lykos debacle, what’s next for psychedelic therapies?Go to article: Compounding pharmacies caught in counterfeit controversyGo to article: How the Covid-19 pandemic will help researchers with the mpox emergencyGo to article: Iterum’s oral sulopenem acceptance hinges on antibiotic stewardship effortsGo to article: Clinical research in the UK must build on industry collaboration, says NIHR directorGo to article: Keytruda and Opdivo: a decade reviewGo to article: Alphial - CPHIGo to article: RephineGo to article: Rephine - CPHIGo to article: Thematic Take: AIGo to article: Thematic Take: contentsGo to article: Foreword: Generative AI as a force of creative destructionGo to article: The road to advanced AI capabilitiesGo to article: AI technology: Market size and growth forecasts Go to article: Timeline: a history of AIGo to article: The impact of AI on the pharma sectorGo to article: Case studies: AI in pharmaGo to article: Latest news: AI in pharmaGo to article: AI boom set to revolutionise healthcare in EuropeGo to article: How NVIDIA grew with the healthcare market instead of pushing into itGo to article: Capturing the genAI boom for drug developmentGo to article: New AI model boosts early osteoporosis diagnosis for ageing populationsGo to article: Impact of AI on metabolic disorder clinical trialsGo to article: Resist temptation to rapidly roll out AI – executives must focus on talent and trainingGo to article: Is AI really helping employees?Go to article: Is your business ready for the rise of AI agents?Go to article: Deal activity related to AI in the pharma industry since 2021Go to article: Sponsored SupplementsGo to article: BEA TechnologiesGo to article: Techniconsult Firenze - CPHIGo to article: Science4TechGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue